NCT04854681 - Phase 1 Trial of the TQB2928 Injection in Patients With Advanced Cancers | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 1, 2021

Primary Completion Date

July 1, 2022

Study Completion Date

December 1, 2022

Conditions

Advanced Solid Tumors and Hematological Malignancies

Interventions

DRUG

TQB2928 Injection

4 weekly IV infusions (Days 1, 8, 15, and 22) of TQB2928 in each 28-day treatment cycle until unacceptable toxicity, documentation of confirmed progressive disease (PD), or subject withdrawal.